- Details
- Andrew Armstrong joins Andrea Miyahira in discussing a retrospective analysis of the prospective multicenter PROPHECY trial of men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide seeking to develop a liquid biopsy using circulating tumor cells (CTCs) that they can associate with outcomes in men with mCRPC and ultimately apply that to a PSMA-tar...
|
- Details
- Renu Eapen, a recipient of the PCF Young Investigator Award, details her groundbreaking project on early use of Lutetium PSMA for high-risk localized prostate cancer. The two-cohort clinical trial involves administering Lutetium PSMA upfront, followed by radical prostatectomy. An integral part of the study is the translational work, analyzing changes in the tumor microenvironment in response to Lu...
|
- Details
- In this discussion, Neal Shore speaks with Alicia Morgans to discuss their experiences and insights on topics ranging from survivorship to new developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Dr. Morgans highlights her work in the EAU session on mCRPC, outlining the significance of PARP inhibitors, the PROpel and MAGNITUDE trials, and the potential role of...
|
- Details
- Oliver Sartor joins Alicia Morgans in a discussion on the implementation of PSMA theranostics and treating patients with lutetium in clinical practices. Drs Morgans and Sartor talk through the logistics of this integration, patient selection, and treatment choice for prolonging survival and improving quality of life. Dr. Sartor also highlights potential novel expanded indications that we may see i...
|
- Details
- Urologist Neal Shore joins Alicia Morgans in a discussion on the integration of lutetium into clinical practices. Dr. Shore reviews the phase 3 VISION trial which led to the approval of Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. They discuss steps to thoughtfully and practically, integrate this new therapeutic into our treatment paradigm. Biographies: Neal Shore, MD...
|
- Details
- Michael Morris joins Alicia Morgans to discuss the clinical implementation of Pluvicto™ (177Lu-PSMA-617) in a way that ensures equity to all patients, regardless of the many factors that could disrupt access. They discuss equity of distribution to all those patients who need it and the availability of PSMA PET scans. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourin...
|
- Details
- Oliver Sartor joins Phillip Koo to discuss the United State FDA approval of Pluvicto™ (177Lu-PSMA-617) as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). They discuss currently enrolling in clinical trials with Pluvicto in the pre-chemotherapy treated mCRPC patient population. They look further into the future discu...
|
- Details
- Phillip Koo is joined by Hossein Jadvar to discuss the Appropriate Use Criteria (AUC) for PSMA PET in prostate cancer. Dr. Jadvar, the first author of the publication, discusses the process of developing the AUC for PSMA PET in prostate cancer and reviews 11 clinical scenarios that may be encountered by ordering professionals when they want to consult the AUC for ordering their imaging. To guide r...
|
- Details
- In this LUGPA CME presentation, Dr Phillip Kuo presents theranostics and its role in prostate cancer treatment. He provides a brief introduction into theranostics, a focus on PSMA, highlighting some select theranostic trials, then delves into a broader vision of what theranostics can mean, particularly to the nuclear medicine committee and PSMA. Biographies: Phillip H. Kuo, MD, Ph.D., Professor of...
|
- Details
- Alicia Morgans and Shahneen Sandhu discuss the advancements in targeted radioligand therapy for prostate cancer. Dr. Sandhu emphasizes the pioneering work done in Germany and her team's contributions in running the first prospective study on lutetium PSMA. Their research reveals significant PSA response rates and quality of life improvements in patients. The conversation also explores the importan...
|
